Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Kv1.3 ion channel blocker shows potential in rare disease
July 2018
SHARING OPTIONS:

SEATTLE—Kv1.3 Therapeutics Inc. shared data at the recent American Academy of Neurology Meeting from sporadic inclusion body myositis patients (sIBM) showing high expression of the Kv1.3 ion channel on lymphocytes from their skeletal muscle biopsies. Kv1.3 is often found on T effector memory cells, which play a role in several T cell-mediated autoimmune disorders. The presence of this ion cannel on lymphocytes in this patient population supports the use of Kv1.3 Therapeutics’ dalazatide as a potential treatment for sIBM. Dalazatide is a highly selective and nearly irreversible inhibitor of the Kv1.3 ion channel.
 
“Dalazatide has demonstrated preclinical activity in multiple preclinical animal models of T cell autoimmune disease and has been found to be safe in early clinical trials. We look forward to clinical trials of dalazatide in sIBM patients,” said Dr. Tahseen Mozaffar, professor of neurology at the University of California, Irvine, lead investigator on the research.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.